Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotac PharmaceuticalsNSE:SOTAC 49 Dividend Yield % is 0.11% as of Aug. 13, 2026, which is 22% above its 10-year median of 0.09. GuruFocus rates NSE:SOTAC with a GF Score™ of 49/100 and a GF Value™ of ₹141.83 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 511 Drug Manufacturers companies, Sotac Pharmaceuticals ranks worse than 96.67% on this metric.
As of today (2026-08-13), the Trailing Annual Dividend Yield of Sotac Pharmaceuticals is 0.11%.
The historical rank and industry rank for Sotac Pharmaceuticals's Dividend Yield % or its related term are showing as below:
NSE:SOTAC'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.09 Med: 0.09 Max: 0.11
Current: 0.11
During the past 7 years, the highest Dividend Yield of Sotac Pharmaceuticals was 0.11%. The lowest was 0.09%. And the median was 0.09%.
NSE:SOTAC's Dividend Yield % is ranked worse than 96.67% of 511
companies
in the Drug Manufacturers industry
Industry Median: 1.94
vs NSE:SOTAC: 0.11
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Sotac Pharmaceuticals Dividend Yield % Related Terms
Sotac Pharmaceuticals Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Sotac Pharmaceuticals's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Sotac Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 0.100000
2025-09-19
2025-09-19
2025-10-29
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Sotac Pharmaceuticals's Trailing Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotac Pharmaceuticals (NSE:SOTAC) has a Dividend Yield % of 0.11% as of Aug. 13, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Sotac Pharmaceuticals and its competitors. This is 22% above median its historical median of 0.09. Over the past decade, Sotac Pharmaceuticals' Dividend Yield % has ranged from 0.09 to 0.11. According to the industry distribution chart, Sotac Pharmaceuticals ranks #494 out of 511 companies in the Drug Manufacturers industry, placing it in the top 96.7%.
Is Sotac Pharmaceuticals' Dividend Yield % too high?
Sotac Pharmaceuticals' current Dividend Yield % of 0.11% is 22% above median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.11. The Drug Manufacturers industry median Dividend Yield % is 1.94. Sotac Pharmaceuticals' value of 0.11% is 94.3% below this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #494 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sotac Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #494 out of 511 companies for Dividend Yield %. This places Sotac Pharmaceuticals in the lower half of its industry. The industry median Dividend Yield % is 1.94. Sotac Pharmaceuticals' value of 0.11% is 94.3% below this benchmark. Historically, Sotac Pharmaceuticals' own Dividend Yield % has ranged from 0.09 to 0.11 over the past decade. While the company's 10-year median is 0.09 vs. the industry median of 1.94, Sotac Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.94, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current Dividend Yield % of 0.11% is 94.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Sotac Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current Dividend Yield % is 0.11%, which is 22% above median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹141.83, compared to a current price of ₹91.95 — trading 35.2% below its estimated fair value. The current Dividend Yield % is 0.11%, which is 22% above median its 10-year median of 0.09 and 94.3% below the Drug Manufacturers industry median of 1.94. Sotac Pharmaceuticals' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Dividend Yield % is 0.11% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹91.95 is trading 35.2% below its estimated GF Value™ of ₹141.83.
GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:SOTAC:
Dividend Yield %: 0.11% (22% above median its 10-year median of 0.09)
GF Value™: ₹141.83 vs. price of ₹91.95 (35.2% below fair value)
Industry Position: 94.3% below the Drug Manufacturers median (#494 of 511)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
49GF Score
Get the complete analysis for NSE:SOTAC
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
